What is the GenomeBreast+ study and how does it differ from GenomeBreast?
GenomeBreast+ is an enhanced genetic test that analyzes a larger number of genes associated with the risk of hereditary breast and ovarian cancer than the standard GenomeBreast test. While Genome Breast primarily focuses on analyzing the BRCA1 and BRCA2 genes, GenomeBreast+ expands its scope to 28 different genes. This includes other genes that also play an important role in cancer predisposition. For example, ATM, CHEK2, PALB2, and many others.
The main difference between the two studies lies in the depth of analysis and the number of genes investigated. GenomeBreast is suitable for those who want to focus only on the most well-known genes associated with breast and ovarian cancer. On the other hand, Genome Breast Plus offers a more comprehensive genetic profile. It includes genes associated with other types of cancer and genetic conditions that can also affect the risk of developing these diseases.
Why should we get tested with GenomeBreast+?
The study is important for people who want a fuller and more detailed picture of their genetic risk. Knowing your complete genetic profile can help you better understand potential risks and make more informed decisions regarding prevention and treatment. Unlike GenomeBreast (which focuses on BRCA genes), GenomeBreast+ provides additional information about other mutations.
The study results could lead to better personalization of medical care and more effective preventive measures. For example, if a test identifies a mutation in the CHEK2 gene, it could indicate a different risk and different monitoring and prevention strategies compared to a mutation in the BRCA1 or BRCA2 genes.
What do we offer with GenomeBreast+?
In collaboration with our partners at NMGenomix, we offer a comprehensive analysis of 28 genes. These genes are associated with various types of hereditary cancers. The test utilizes state-of-the-art technologies. This includes next-generation sequencing (NGS) to ensure exceptionally high accuracy and reliability of the results. This means that the analysis covers over 99% of the genetic material that can be tested for mutations.
Additionally, GenomeBreast+ includes consultation with a medical geneticist before and after the test. This ensures that patients understand the results and how they may impact their health. The consultation can help develop personalized monitoring and prevention strategies tailored to the patient's specific genetic profile.
Who should be tested with GenomeBreast+?
GenomeBreast+ is a recommended test for individuals with a family history of breast, ovarian, or other related cancers. It is also suitable for those diagnosed with cancer at a young age, have multiple relatives with cancer, or show signs of hereditary predisposition. This is particularly important for individuals who have already undergone the standard Genome Breast testing and are seeking more detailed information about their genetic health.
What information does the study provide?
GenomeBreast+ provides detailed information on genetic mutations in 28 genes associated with breast and ovarian cancer, as well as other types of cancer. This information includes not only the presence of mutations but also how they can affect the risk of developing the disease. The results of the study can be used to develop personalized strategies for monitoring, prevention, and treatment.
In conclusion, GenomeBreast+ offers a broader and deeper insight into genetic cancer risk compared to the standard GenomeBreast test. For those seeking a more complete genetic picture, this test is the ideal choice. For more information and details about the test, you can call tel. ☎️ 0878 500 730.
